This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Millan, M. J. Articles by Gobert, A. Search for Related Content PubMed PubMed Citation Articles by Millan, M. J. Articles by Gobert, A. Social Bookmarking                         What's this?

Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents

Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125, Chemin de Ronde 78290, Croissy-sur-Seine, France

Françoise Lejeune

Alain Gobert

Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, Croissy-sur-Seine, France

The frontal cortex (FCX) plays a key role in processes that control mood, cognition and motor behaviour, functions which are compromised in depression, schizophrenia and other psychiatric disorders. In this regard, there is considerable evidence that a perturbation of monoaminergic input to the FCX is involved in the pathogenesis of these states. Correspondingly, the modulation of monoaminergic transmission in the FCX and other corticolimbic structures plays an important role in the actions of antipsychotic and antidepressant agents. In order to further understand the significance of monoaminergic systems in psychiatric disorders and their treatment, it is essential to characterize mechanisms underlying their modulation. Within this framework, the present commentary focuses on our electrophysiological and dialysis analyses of the complex and reciprocal pattern of autoand heteroreceptor mediated control of dopaminergic, noradrenergic and serotonergic transmission in the FCX. The delineation of such interactions provides a framework for an interpretation of the influence of diverse classes of antidepressant agent upon extracellular levels of dopamine, noradrenaline and serotonin in FCX. Moreover, it also generates important insights into strategies for the potential improvement in the therapeutic profiles of antidepressant agents.

Key Words: antidepressant • depression • dopamine • frontal cortex • monoamines • mood • noradrenaline • selective serotonin • reuptake inhibitor • serotonin • tricyclic

Journal of Psychopharmacology, Vol. 14, No. 2, 114-138 (2000)
DOI: 10.1177/026988110001400202


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. R Dolder, M. Nelson, and M. Snider Agomelatine Treatment of Major Depressive Disorder Ann. Pharmacother., December 1, 2008; 42(12): 1822 - 1831. [Abstract] [Full Text] [PDF]

				M. J. Millan, P. Svenningsson, C. R. Ashby Jr., M. Hill, M. Egeland, A. Dekeyne, M. Brocco, B. Di Cara, F. Lejeune, N. Thomasson, et al. S33138 [N-[4-[2-[(3aS,9bR)-8-Cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent. II. A Neurochemical, Electrophysiological and Behavioral Characterization in Vivo J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 600 - 611. [Abstract] [Full Text] [PDF]

				E. Berrocoso and J. A. Mico In Vivo Effect of Venlafaxine on Locus Coeruleus Neurons: Role of Opioid, {alpha}2-Adrenergic, and 5-Hydroxytryptamine1A Receptors J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 101 - 107. [Abstract] [Full Text] [PDF]

				G. Bonanno, R. Giambelli, L. Raiteri, E. Tiraboschi, S. Zappettini, L. Musazzi, M. Raiteri, G. Racagni, and M. Popoli Chronic Antidepressants Reduce Depolarization-Evoked Glutamate Release and Protein Interactions Favoring Formation of SNARE Complex in Hippocampus J. Neurosci., March 30, 2005; 25(13): 3270 - 3279. [Abstract] [Full Text] [PDF]

				M. J. Millan, A. Gobert, S. Roux, R. Porsolt, A. Meneses, M. Carli, B. Di Cara, R. Jaffard, J.-M. Rivet, P. Lestage, et al. The Serotonin1A Receptor Partial Agonist S15535 [4-(Benzodioxan-5-yl)1-(indan-2-yl)piperazine] Enhances Cholinergic Transmission and Cognitive Function in Rodents: A Combined Neurochemical and Behavioral Analysis J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 190 - 203. [Abstract] [Full Text] [PDF]

				M. J. Millan, D. Cussac, A. Gobert, F. Lejeune, J.-M. Rivet, C. M. La Cour, A. Newman-Tancredi, and J.-L. Peglion S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with Ropinirole J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 903 - 920. [Abstract] [Full Text] [PDF]

				M. J. Millan, A. Gobert, F. Lejeune, A. Dekeyne, A. Newman-Tancredi, V. Pasteau, J.-M. Rivet, and D. Cussac The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 954 - 964. [Abstract] [Full Text] [PDF]

				A. Gobert, B. Di Cara, L. Cistarelli, and M. J. Millan Piribedil Enhances Frontocortical and Hippocampal Release of Acetylcholine in Freely Moving Rats by Blockade of alpha 2A-Adrenoceptors: A Dialysis Comparison to Talipexole and Quinelorane in the Absence of Acetylcholinesterase Inhibitors J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 338 - 346. [Abstract] [Full Text]

				F. Yasuno, T. Suhara, T. Nakayama, T. Ichimiya, Y. Okubo, A. Takano, T. Ando, M. Inoue, J. Maeda, and K. Suzuki Inhibitory Effect of Hippocampal 5-HT1A Receptors on Human Explicit Memory Am J Psychiatry, February 1, 2003; 160(2): 334 - 340. [Abstract] [Full Text] [PDF]

				M. J. Millan, L. Maiofiss, D. Cussac, V. Audinot, J.-A. Boutin, and A. Newman-Tancredi Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 791 - 804. [Abstract] [Full Text] [PDF]

				A. Newman-Tancredi, D. Cussac, V. Audinot, J.-P. Nicolas, F. De Ceuninck, J.-A. Boutin, and M. J. Millan Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and alpha 1/alpha 2-Adrenoceptor J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 805 - 814. [Abstract] [Full Text] [PDF]

				A. Newman-Tancredi, D. Cussac, Y. Quentric, M. Touzard, L. Verriele, N. Carpentier, and M. J. Millan Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 815 - 822. [Abstract] [Full Text] [PDF]

				M. J. Millan, A. Gobert, F. Lejeune, A. Newman-Tancredi, J.-M. Rivet, A. Auclair, and J.-L. Peglion S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: I. Receptor Binding, Electrophysiological, and Neurochemical Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 565 - 580. [Abstract] [Full Text] [PDF]

				M. J. Millan, A. Dekeyne, M. Papp, C. D. L. Rochelle, C. MacSweeny, J.-L. Peglion, and M. Brocco S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: II. Behavioral Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 581 - 591. [Abstract] [Full Text] [PDF]

				M. J. Millan, D. Cussac, G. Milligan, C. Carr, V. Audinot, A. Gobert, F.'o. Lejeune, J.-M. Rivet, M. Brocco, D. Duqueyroix, et al. Antiparkinsonian Agent Piribedil Displays Antagonist Properties at Native, Rat, and Cloned, Human alpha 2-Adrenoceptors: Cellular and Functional Characterization J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 876 - 887. [Abstract] [Full Text]

				M. J. Millan Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 853 - 861. [Abstract] [Full Text]

				M. J. Millan, F. Lejeune, A. Gobert, M. Brocco, A. Auclair, C. Bosc, J.-M. Rivet, J.-M. Lacoste, A. Cordi, and A. Dekeyne S18616, a Highly Potent Spiroimidazoline Agonist at alpha 2-Adrenoceptors: II. Influence on Monoaminergic Transmission, Motor Function, and Anxiety in Comparison with Dexmedetomidine and Clonidine J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1206 - 1222. [Abstract] [Full Text]